Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving

This publication has 29 references indexed in Scilit:

• Hepatitis C Disease Burden in the United States in the era of oral direct‐acting antivirals
  Hepatology, 2016
• Cost-effectiveness of sofosbuvir-based treatments for chronic hepatitis C in the US
  BMC Gastroenterology, 2015
• Limited Access to New Hepatitis C Virus Treatment Under State Medicaid Programs
  Annals of Internal Medicine, 2015
• Cost-Effectiveness Analysis of Sofosbuvir Compared to Current Standard Treatment in Swiss Patients with Chronic Hepatitis C
  PLOS ONE, 2015
• Sofosbuvir-Based Treatment Regimens for Chronic, Genotype 1 Hepatitis C Virus Infection in U.S. Incarcerated Populations
  Annals of Internal Medicine, 2014
• Cost Utility of Telaprevir–PR (Peginterferon–Ribavirin) Versus Boceprevir–PR and Versus PR Alone in Chronic Hepatitis C in The Netherlands
  Applied Health Economics and Health Policy, 2014
• The Changing Burden of Hepatitis C Virus Infection in the United States: Model-Based Predictions
  Annals of Internal Medicine, 2014
• Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement
  BMC Medicine, 2013
• Distribution of hepatitis C virus genotypes in a diverse US integrated health care population
  Journal of Medical Virology, 2012
• Chronic Hepatitis C Infection
  New England Journal of Medicine, 2011